The UAE has become the second country in the world to approve the new lung cancer drug 'Lumakras'.
The Ministry of Health and Prevention (MoHAP) has cleared the registration and use of the drug, which recently received the approval of the US Food and Drug Administration (FDA).
It will help speed up the treatment plan of patients in the UAE and improve their quality of life.
Lumakras, manufactured by Amgen, is prescribed to adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), who have received at least one previous cancer therapy.
It is supplied as film-coated tablets for oral use containing 120 mg of sotorasib.
Minor damage reported after missile interception in Abu Dhabi
UAE responds to new wave of missile threats
UAE: Iranian community part of nation’s diverse social fabric
UAE and US Presidents discuss regional developments
UAE defence systems intercept missile and UAV threats
UAE participates in 43rd session of Council of Arab Interior Ministers
Sheikh Hamdan directs move to set up unified platform for government services
Dubai to roll out free parking, discounted transport fares for senior Emiratis
One dead in debris incident at farm in Fujairah
One injured from fallen sharpnel in Umm Al Quwain
UAE carriers issue entry and transit restrictions for Iranian nationals
UAE intercepts 5 ballistic missiles and 35 drones on Wednesday
H.H. Sheikh Khaled reviews operational continuity of ADNOC facilities
UAE forecasts strong winds, rough sea conditions
UAE President receives call from Russian President
UAE joins UN Human Rights Council consultative group
Abdullah bin Zayed, Greek Defence Minister discuss Iran developments
Economy Minister confirms stable food prices, secure supply
UAE extends distance learning for universities until April 17
